Multiple system atrophy is a rare, rapidly progressive neurodegenerative disease with no disease-modifying treatment, which makes the question of preserving future options unusually pressing for the patients and physicians who face it. Mayo Clinic’s Phase 2 trial, NCT05167721, is studying autologous adipose-derived mesenchymal stem cells administered intrathecally in MSA. What follows is what treating physicians need to know about the trial as registered, the state of the evidence, and the clinical-timing consideration that banking raises in a disease that narrows the window for tissue harvest as it progresses.
TLDR: NCT05167721 is a Mayo Clinic Phase 2, randomized, double-blind, placebo-controlled trial of intrathecally administered autologous mesenchymal stem cells in multiple system atrophy, using adipose-derived cells, with enrollment of 71 and an estimated completion in December 2026; its status is active, not recruiting. There is no FDA-approved MSC therapy for MSA, and Phase 2 status means preliminary efficacy and safety, not standard of care. Because MSA progresses quickly and harvest requires a patient well enough for a minor procedure, the banking-timing window narrows as the disease advances. Banking adipose tissue does not enroll a patient in therapy and does not guarantee any future eligibility, access, or benefit.
Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures for any disease. Banking adipose tissue today does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. No adipose-derived stem cell product currently holds FDA approval for multiple system atrophy or any condition discussed here. This therapy is investigational. All content is for educational purposes only and does not constitute medical advice. Patients must consult their own licensed healthcare professionals regarding all medical decisions.
A single-trial briefing has to be careful about two things: stating only what the registered record supports, and keeping the banking-timing argument on the right side of the line between a clinical consideration and a therapeutic promise. The timing point in MSA is genuine, harvest feasibility really does decline with disease progression, but it is a statement about preserving an option, not about what that option will deliver.
What Is Multiple System Atrophy?
MSA is a rare, progressive neurodegenerative disease characterized by autonomic dysfunction, parkinsonism, and cerebellar ataxia. Median survival after diagnosis is commonly cited in the range of several years, and there is no currently approved disease-modifying therapy; management is supportive. The rationale for studying MSCs in MSA rests on preclinical and early-phase work suggesting possible neuroprotective and immunomodulatory effects relevant to neurodegeneration, though that rationale remains investigational rather than established. The distinction between investigational mechanism and proven benefit is exactly what the trial phases are designed to test, as the explainer on clinical trial phases lays out.
The Mayo Clinic Trial: NCT05167721
As registered on ClinicalTrials.gov, the trial is titled a randomized, double-blind, placebo-controlled adaptive-design trial of intrathecally administered autologous mesenchymal stem cells in multiple system atrophy. The lead sponsor is Mayo Clinic. The cells are adipose-derived and autologous, administered intrathecally, into the spinal fluid, rather than intravenously. Enrollment is listed at 71 participants, the study began in December 2021, and estimated completion is December 2026. Its current status is active, not recruiting, which means the trial is ongoing but not enrolling new participants at this time.
| Field | Detail (as registered) |
|---|---|
| NCT number | NCT05167721 |
| Condition | Multiple system atrophy |
| Phase | Phase 2 |
| Sponsor | Mayo Clinic |
| Cell type | Autologous adipose-derived MSC |
| Route | Intrathecal |
| Design | Randomized, double-blind, placebo-controlled, adaptive |
| Enrollment | 71 |
| Status | Active, not recruiting |
| Estimated completion | December 2026 |
Because the trial is active but not recruiting, a physician with a potential candidate should confirm the current status directly at the trial record before initiating any referral conversation, since enrollment status can change.
What the Evidence Base Looks Like
This Phase 2 trial follows earlier-phase work on MSC therapy in MSA and related neurodegenerative conditions, including published intra-arterial and intrathecal MSC studies in MSA cohorts. The honest characterization is precise: there is no FDA-approved MSC therapy for MSA, this is an active investigational trial, and Phase 2 trials are designed to assess preliminary efficacy and safety rather than to establish a standard of care. Earlier MSA MSC work has reported both signals of interest and notable adverse events, which is part of why a controlled Phase 2 with an adaptive design is the appropriate next step rather than broader use. Physicians should treat the current evidence as hypothesis-testing, not as a basis for representing benefit to patients.
The Banking-Timing Consideration in MSA
Here the disease course creates a real clinical-timing point. MSA can progress to substantial functional loss within a few years of diagnosis, and adipose-tissue harvest requires a patient well enough to tolerate a minor outpatient procedure. A patient diagnosed in an early-to-moderate stage who, with their physician, has identified future autologous cell-therapy participation as a goal is in a different position than one whose disease has advanced past the point where harvest is feasible. Once harvest is no longer medically appropriate, the autologous option is foreclosed regardless of what trials or therapies later become available. The correct framing is narrow and must stay narrow: banking early preserves an option, not banking forecloses it, and preserving the option is not the same as securing a treatment. Nothing about banking should be presented to an MSA patient as disease-modifying.
How the Treating Physician Interacts with a Trial Like This
Referring a patient to an active trial means reviewing the inclusion and exclusion criteria and contacting the trial’s coordinator or principal investigator, recognizing that an active-but-not-recruiting status may mean no current enrollment slot. Where a patient does not qualify or the trial is not enrolling, expanded access may be a separate route, pursued through a single-patient IND or a sponsor request, though access is never assured and depends on the sponsor’s willingness to provide the investigational product. A physician who has banked a patient’s tissue should document the existence of that banked sample in the chart so it is available as context if a trial referral is ever pursued.
Physician Action Checklist
- Verify current trial status and enrollment at the NCT05167721 record.
- Review inclusion and exclusion criteria for any potential MSA candidate.
- Contact the Mayo Clinic trial coordinator if a patient may qualify.
- If the patient does not qualify, review expanded-access options.
- Discuss banking timing with the patient while harvest is still clinically feasible.
- Document the banking discussion and decision in the chart, whatever the patient decides.
Frequently Asked Questions
Is this trial enrolling new patients?
As registered, its status is active, not recruiting, which means it is ongoing but not currently enrolling. Status can change, so confirm at the live trial record before pursuing a referral.
How are the cells given?
Intrathecally, into the spinal fluid, not by intravenous infusion. The cells are autologous and adipose-derived.
Does banking tissue mean an MSA patient can join this trial?
No. Banking preserves an autologous sample, but eligibility is set by the trial’s own criteria, the trial may not be enrolling, and trial-specific manufacturing requirements may not be met by third-party banked tissue. The timing argument is about keeping an option open, not securing entry.
Key Takeaways
NCT05167721 is a Mayo Clinic Phase 2, randomized, double-blind, placebo-controlled trial of intrathecal autologous adipose-derived MSCs in MSA, enrolling 71, active but not recruiting, with estimated completion in December 2026. The evidence is investigational: no MSC therapy is FDA-approved for MSA, and Phase 2 tests preliminary efficacy and safety rather than establishing benefit. The genuine clinical wrinkle in MSA is timing, because the disease narrows the window in which harvest is feasible, so the banking conversation, if it is going to happen at all, belongs in the early-to-moderate stage. But that point has to be held precisely: banking preserves an option that disease progression would otherwise foreclose, and it is not a treatment and not disease-modifying. It remains a preservation decision separate from therapy, with no guarantee of future benefit.
Save My Fat operates as a tissue preservation service, not a medical practice or treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, and Nevada governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.
Physicians counseling MSA patients on preserving future options can contact Save My Fat to discuss the tissue-preservation side.
Save My Fat partners with L2 Bio for laboratory processing and storage.
This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including neurology and neurosurgery input is required before publication. Please consult your neurologist or neurosurgeon before making any decisions about neurologic treatment or research participation.
